EVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Evaxion A/S
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 5, 2026
$3.33+0.50 (+17.67%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Debt
Borrowings on the balance sheet, Dec 31, 2025
Total debt
$5.54M
$190.00K due within a year
Net debt
-$17.70M
After $23.23M of cash
Implied interest rate
58.33%
FY2025 interest ÷ average debt
Interest coverage
-2.3×
FY2025 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
Bond issues
Individual notes and bonds outstanding
Bond-level data is not connected yet
Coupon, maturity and amount of each note will come from the debt footnote in Evaxion A/S's annual report. Trading prices and yields need FINRA TRACE data.